r-n-jРоссийский неврологический журналRussian neurological journal2658-79472686-7192МИА10.30629/2658-7947-2021-26-2-11-16r-n-j-165Research ArticleОБЗОРЫREVIEWSПрепарат моноклональных антител эренумаб в профилактике мигрени: обзор новых данныхMonoclonal antibody erenumab for migraine prevention: a review of new datahttps://orcid.org/0000-0002-6219-3384АртеменкоА. Р.АrtemenkоA. R.

Москва

Moscow

aartemenko@gmail.comhttps://orcid.org/0000-0002-3030-1918ПлиеваА. М.PlievaA. M.

Москва

Moscow

plieva_amilta@mail.ruhttps://orcid.org/0000-0001-6878-4938ШмидтД. А.ShmidtD. A.

Москва

Moscow

shmidt.daria2012@yandex.ruhttps://orcid.org/0000-0002-3638-6094ЕкушеваЕ. В.EkushevaE. V.

Москва

Moscow

ekushevaev@mail.ruhttps://orcid.org/0000-0002-7269-9100КуренковА. Л.KurenkovA. L.

Москва

Moscow

alkurenkov@gmail.comhttps://orcid.org/0000-0003-2958-4479ДаниловАл. Б.DanilovAl. B.

Москва

Moscow

danilov@intermeda.ruПервый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationФедеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА РоссииРоссияFederal Scientifi c Clinical Center of the Federal Medical and Biological Agency of RussiaRussian FederationФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава РоссииРоссияNational Medical Research Center for Children’s HealthRussian Federation2021290520212621116Copyright © Артеменко А.Р., Плиева А.М., Шмидт Д.А., Екушева Е.В., Куренков А.Л., Данилов А.Б., 20212021Артеменко А.Р., Плиева А.М., Шмидт Д.А., Екушева Е.В., Куренков А.Л., Данилов А.Б.Аrtemenkо A.R., Plieva A.M., Shmidt D.A., Ekusheva E.V., Kurenkov A.L., Danilov A.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.r-n-j.com/jour/article/view/165

Моноклональные антитела (МАТ) к кальцитонин-ген родственному пептиду (КГРП) (Calcitoningene related peptide) стали первым классом профилактических препаратов, специально разработанных для лечения мигрени. В обзоре рассматривается механизм действия МАТ с позиций современной концепции патофизиологии мигрени, обсуждаются вопросы иммуногенности и лекарственного взаимодействия. Эренумаб, препарат из класса МAТ к КГРП, стал доступен в России с февраля 2020 г. Действие эренумаба связано с блокированием рецептора КГРП, он единственный из существующих МАТ конкурирует с молекулой КГРП за связывание с рецептором. В статье обобщены фармакологические характеристики эренумаба, представлены результаты клинических исследований с акцентом на новейшие публикации последнего года. Представлена роль этого метода лечения в условиях реальной клинической практики: описаны эффективность и безопасность эренумаба при разных формах мигрени, показана возможность перехода («обратной трансформации») из хронической мигрени в эпизодическую форму на терапии этим препаратом, представлены результаты лечения труднокурабельных случаев при резистентной и рефрактерной мигрени. Эренумаб является единственным из препаратов МАТ, по данным исследований которого опубликованы результаты пятилетних клинических наблюдений, доказавших устойчивую эффективность и безопасность при долгосрочном применении, а также экономическую целесообразность его использования.

Monoclonal antibodies (mAT) to calcitonin-gene-related peptide (CGRP) have become the fi rst class of preventive medications specifically designed to treat migraines. The article examines the mechanism of action of mAT from the standpoint of a modern view of the pathophysiology of migraine, discusses the issues of immunogenicity and drug interaction. The review describes in detail the monoclonal antibody erenumab, which became available in Russia from February 2020. The action of erenumab is associated with blocking the CGRP receptor, since it is the only one of the existing mAT that competes with the CGRP molecule for binding to the receptor. This review summarizes the pharmacological characteristics of erenumab, presents in detail the results of clinical trials with an emphasis on the publications of the last year. The article also presents the role of this method of treatment in real clinical practice: the eff ectiveness and safety of erenumab in various forms of migraine are described in detail, the possibility of transition (“reverse transformation”) from chronic migraine to episodic form on erenumab therapy is shown, impressive results of treatment of intractable cases in resistant and refractory migraines are presented. Erenumab is the only one of the mAT drugs for which the results of five-year clinical observations have been published, which have proved the sustained effectiveness and safety in long-term use, as well as the economic feasibility of using this therapeutic approach.

моноклональные антителаэпизодическаяхроническаярезистентнаярефрактерная мигреньголовная больлекарственно-индуцированная головная больиммуногенностьлекарственное взаимодействиеmonoclonal antibodiesepisodicchronicresistantrefractory migrainemedication overuse headacheimmunogenicitydrug interactionReferencesCharles A., Pozo-Rosich P. Targeting calcitonin generelated peptide: a new era in migraine therapy. Lancet. 2019;394(10210):1765–1774. https://doi.org/10.1016/S0140-6736(19)32504-8Charles A., Pozo-Rosich P. Targeting calcitonin generelated peptide: a new era in migraine therapy. Lancet. 2019;394(10210):1765–1774. https://doi.org/10.1016/S0140-6736(19)32504-8Sirbu C.A., Ghinescu M.C., Axelerad A.D., Sirbu A.M., Ionita-Radu F. A new era for monoclonal antibodies with applications in neurology (Review). Exp. Ther. Med. 2021;21(1):86. https://doi.org/10.3892/etm.2020.9519Sirbu C.A., Ghinescu M.C., Axelerad A.D., Sirbu A.M., Ionita-Radu F. A new era for monoclonal antibodies with applications in neurology (Review). Exp. Ther. Med. 2021;21(1):86. https://doi.org/10.3892/etm.2020.9519Wolff -Holz E., Tiitso K., Vleminckx C., Weise M. Evolution of the EU biosimilar framework: Past and future. BioDrugs. 2019;33:621–634.Wolff -Holz E., Tiitso K., Vleminckx C., Weise M. Evolution of the EU biosimilar framework: Past and future. BioDrugs. 2019;33:621–634.Leung D., Wurst J.M., Liu T., Martinez R.M., Datta-Mannan A., Feng Y. Antibodies (Basel). Antibody Conjugates-Recent Advances and Future Innovations. 2020;9(1):2. https://doi.org/10.3390/antib9010002Leung D., Wurst J.M., Liu T., Martinez R.M., Datta-Mannan A., Feng Y. Antibodies (Basel). Antibody Conjugates-Recent Advances and Future Innovations. 2020;9(1):2. https://doi.org/10.3390/antib9010002Disease G.B.D., Injury I., Prevalence C. Global, regional, and national incidence, prevalence, andyears lived with disability for 328 diseases andinjuries for 195 countries, 1990–2016: a systematicanalysis for the global burden of Disease study. 2016. Lancet. 2017;390(10100):1211–59.Disease G.B.D., Injury I., Prevalence C. Global, regional, and national incidence, prevalence, andyears lived with disability for 328 diseases andinjuries for 195 countries, 1990–2016: a systematicanalysis for the global burden of Disease study. 2016. Lancet. 2017;390(10100):1211–59.Филатова Е.Г., Осипова В.В., Табеева Г.Р. Парфенов В.А., Екушева Е.В., Азимова Ю.Э. и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):4–14. https://doi.org/10.14412/2074-2711-2020-4-4-14Filatova E.G., Osipova V.V., Tabeeva G.R., Parfenov V.A., Ekusheva E.V., Azimova Yu.E. et al. Diagnosis and treatment of migraine: Russian experts’ recommendations. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):4–14 (In Russian). https://doi.org/10.14412/2074-2711-2020-4-4-14Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–182. https://doi.org/10.1016/S1474-4422(17)30435-0Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–182. https://doi.org/10.1016/S1474-4422(17)30435-0Ashina M., Goadsby P.J., Reuter U., Silberstein S., Dodick D.W., Xue F. et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur. J. Neurol. 2021 Jan 5. https://doi.org/10.1111/ene.14715.Ashina M., Goadsby P.J., Reuter U., Silberstein S., Dodick D.W., Xue F. et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur. J. Neurol. 2021 Jan 5. https://doi.org/10.1111/ene.14715.Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55.Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55.Goadsby P.J., Reuter U., Hallstrom Y., Broessner G., Bonner J.H., Zhang F. et al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 2017;377(22):2123–2132. https://doi.org/10.1056/NEJMoa1705848Goadsby P.J., Reuter U., Hallstrom Y., Broessner G., Bonner J.H., Zhang F. et al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 2017;377(22):2123–2132. https://doi.org/10.1056/NEJMoa1705848Dodick D.W., Ashina M., Brandes J.L., Kudrow D., Lanteri- Minet M., Osipova V. et al. ARISE: a phase3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–37.Dodick D.W., Ashina M., Brandes J.L., Kudrow D., Lanteri- Minet M., Osipova V. et al. ARISE: a phase3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–37.Tepper S., Ashina M., Reuter U., Brandes J.L., Dolezil D., Silberstein S. et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434.Tepper S., Ashina M., Reuter U., Brandes J.L., Dolezil D., Silberstein S. et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434.Goadsby P.J., Reuter U., Hallstrom Y., Broessner G., Bonner J.H., Zhang F. et al. One-year sustained efficacy of erenumab in episodic migraine. Results of the STRIVE study. Neurology. 2020;95:e469-e479. https://doi.org/10.1212/WNL.0000000000010019Goadsby P.J., Reuter U., Hallstrom Y., Broessner G., Bonner J.H., Zhang F. et al. One-year sustained efficacy of erenumab in episodic migraine. Results of the STRIVE study. Neurology. 2020;95:e469-e479. https://doi.org/10.1212/WNL.0000000000010019Ashina M., Goadsby P.J, Reuter U., Silberstein S., Dodick D., Rippon G.A. et al. Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019;39(11):1455–1464. DOI: 10.1177/0333102419854082.Ashina M., Goadsby P.J, Reuter U., Silberstein S., Dodick D., Rippon G.A. et al. Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019;39(11):1455–1464. DOI: 10.1177/0333102419854082.Ziegeler C., Mehnert J., Asmussen K., May A. Central effects of erenumab in migraine patients: An event-related functional imaging study. Neurology. 2020;95(20):e2794–e2802. https://doi.org/10.1212/WNL.0000000000010740Ziegeler C., Mehnert J., Asmussen K., May A. Central effects of erenumab in migraine patients: An event-related functional imaging study. Neurology. 2020;95(20):e2794–e2802. https://doi.org/10.1212/WNL.0000000000010740Jain S., Silberstein S.D. Invited Commentary on Preventive Anti-MigraineTherapy (PAMT). Curr. Treat. Options Neurol. 2019;21:14. https://doi.org/10.1007/s11940-019-0555-4Jain S., Silberstein S.D. Invited Commentary on Preventive Anti-MigraineTherapy (PAMT). Curr. Treat. Options Neurol. 2019;21:14. https://doi.org/10.1007/s11940-019-0555-4Cohen J.M., Ning X., Kessle Y., Rasamoelisolo M., Campos V.R., Seminerio M.J. et al. Immunogenicity of biologic therapies for migraine: a review of current evidence. J. Headache Pain. 2021;22(1):3. https://doi.org/10.1186/s10194-020-01211-5Cohen J.M., Ning X., Kessle Y., Rasamoelisolo M., Campos V.R., Seminerio M.J. et al. Immunogenicity of biologic therapies for migraine: a review of current evidence. J. Headache Pain. 2021;22(1):3. https://doi.org/10.1186/s10194-020-01211-5Vargas B., Starling A., Silberstein S. Erenumab Immunogenicity: a Pooled Analysis of Phase 2 and Phase 3 Migraine Prevention Clinical Trials (P4.098). Neurology. 2018;90 (15 Supplement) P4.098.Vargas B., Starling A., Silberstein S. Erenumab Immunogenicity: a Pooled Analysis of Phase 2 and Phase 3 Migraine Prevention Clinical Trials (P4.098). Neurology. 2018;90 (15 Supplement) P4.098.Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug–drug interactions of new anti-migraine drugs — lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12:1180. https://doi.org/10.3390/pharmaceutics12121180; www.mdpi.com/journal/pharmaceuticsSzkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug–drug interactions of new anti-migraine drugs — lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12:1180. https://doi.org/10.3390/pharmaceutics12121180; www.mdpi.com/journal/pharmaceuticsSacco S., Bendtsen L., Ashina M., Reuter U., Terwindt G., Mitsikostas D.D. et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain. 2019;20(1):6. https://doi.org/10.1186/s10194-018-0955-ySacco S., Bendtsen L., Ashina M., Reuter U., Terwindt G., Mitsikostas D.D. et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain. 2019;20(1):6. https://doi.org/10.1186/s10194-018-0955-yTepper S.J., Ashina M., Reuter U., Brandes J.L., Doleži D., Silberstein S.D. et al. Long-term safety and effi cacy of erenumab in patients with chronic migraine: Results from a 52-week, openlabel extension study. Cephalalgia. 2020;40(6):543–553. https://doi.org/10.1177/0333102420912726Tepper S.J., Ashina M., Reuter U., Brandes J.L., Doleži D., Silberstein S.D. et al. Long-term safety and effi cacy of erenumab in patients with chronic migraine: Results from a 52-week, openlabel extension study. Cephalalgia. 2020;40(6):543–553. https://doi.org/10.1177/0333102420912726Lipton R.B., Tepper S.J., Silberstein S.D., Kudrow D., Ashina M., Reuter U. et al. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia. 2021;41(1):6–16. DOI: 10.1177/0333102420973994Lipton R.B., Tepper S.J., Silberstein S.D., Kudrow D., Ashina M., Reuter U. et al. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia. 2021;41(1):6–16. DOI: 10.1177/0333102420973994Raff aelli B., Mussetto V., Israel H., Neeb L., Reuter U. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J. Headache Pain. 2019;20(1):66. https://doi.org/10.1186/s10194-019-1018-8Raff aelli B., Mussetto V., Israel H., Neeb L., Reuter U. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J. Headache Pain. 2019;20(1):66. https://doi.org/10.1186/s10194-019-1018-8De Matteis E., Aff aitati G., Frattale I., Caponnetto V., Pistoia F., Giamberardino M.A. et al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol. Sci. 2021 Jan 2. https://doi.org/10.1007/s10072-020-05022-zDe Matteis E., Aff aitati G., Frattale I., Caponnetto V., Pistoia F., Giamberardino M.A. et al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol. Sci. 2021 Jan 2. https://doi.org/10.1007/s10072-020-05022-zSacco S., Braschinsky M., Ducros A., Lampl C., Little P., Maassen van den Brink A. et al. European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J. Headache Pain. 2020;21(1):76. https://doi.org/10.1186/s10194-020-01130-5Sacco S., Braschinsky M., Ducros A., Lampl C., Little P., Maassen van den Brink A. et al. European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J. Headache Pain. 2020;21(1):76. https://doi.org/10.1186/s10194-020-01130-5Lambru G., Hill B., Murphy M., Tylova I., Andreou A.P. A prospective real-world analysis of erenumab in refractory chronic migraine. J. Headache Pain. 2020;21:61. https://doi.org/10.1186/s10194-020-01127-0Lambru G., Hill B., Murphy M., Tylova I., Andreou A.P. A prospective real-world analysis of erenumab in refractory chronic migraine. J. Headache Pain. 2020;21:61. https://doi.org/10.1186/s10194-020-01127-0Talbot J., Stuckey R., Crawford L., Weatherby S., Mullin S. Improvements in pain, medication use and quality of life in onabotulinumtoxinA- resistant chronic migraine patients following erenumab treatment — real world outcomes. J. Headache Pain. 2021;22(1):5. https://doi.org/10.1186/s10194-020-01214-2Talbot J., Stuckey R., Crawford L., Weatherby S., Mullin S. Improvements in pain, medication use and quality of life in onabotulinumtoxinA- resistant chronic migraine patients following erenumab treatment — real world outcomes. J. Headache Pain. 2021;22(1):5. https://doi.org/10.1186/s10194-020-01214-2Russo A., Silvestro M., Scotto di Clemente F., Trojsi F., Bisecco A., Bonavita S. et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive realworld experience. J. Headache Pain. 2020;21(1):69. https://doi.org/10.1186/s10194-020-01143-0Russo A., Silvestro M., Scotto di Clemente F., Trojsi F., Bisecco A., Bonavita S. et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive realworld experience. J. Headache Pain. 2020;21(1):69. https://doi.org/10.1186/s10194-020-01143-0Mahon R., Lang A., Vo P., Huels J., Cooney P., Danyliv A. et al. Cost-effectiveness of erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics. 2021;39(3):357–372. https://doi.org/10.1007/s40273-020-00996-2Mahon R., Lang A., Vo P., Huels J., Cooney P., Danyliv A. et al. Cost-effectiveness of erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics. 2021;39(3):357–372. https://doi.org/10.1007/s40273-020-00996-2Tepper S.J., Diener H.C., Ashina M., Brandes J.L., Friedman D.I., Reuter U. et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019;92(20):e2309-e2320. https://doi.org/10.1212/WNL.0000000000007497Tepper S.J., Diener H.C., Ashina M., Brandes J.L., Friedman D.I., Reuter U. et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019;92(20):e2309-e2320. https://doi.org/10.1212/WNL.0000000000007497

The authors declare that there are no conflicts of interest present.